Publications

Comparison of Broth Microdilution (BMD) and Disk Diffusion (DD) Methods for Susceptibility Testing of Acinetobacter spp. (Acb) Collected Worldwide, Lead author: Swenson J, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Quality Control Guidelines for Broth Microdilution and Disk Diffusion Susceptibility Testing for Polymixin B and Colistin, Lead author: Jones RN, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Comparisons of Inter-Method Susceptibility Testing Accuracy for LBM415 (NVP PDF-713) Using 2,625 Recent Clinical Isolates, Lead author: Fritsche TR, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Campylobacter spp. Susceptibility Testing: A Multi Site Evaluation of Broth Microdilution Methods Compared to the Agar Dilution Method, Lead author: Knapp C, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Re-Evaluation of Enterobacteriaceae Regression/Scattergrams Using ESBL-Enriched Populations Tested against Eight Beta-Lactams, Lead author: Deshpande LM, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

International Validation of Alternative Disk Diffusion Methods for Detecting mecA-Mediated Oxacillin (OX) Resistance (R) in Staphylococci: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Comparative Activity of Dalbavancin Tested against 7,771 Isolates from the USA and Europe (2003), Lead author: Jones RN, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Antimicrobial Activity of Doripenem (DOR) against Multi-Drug Resistant (MDR) Pseudomonas aeruginosa (PSA) and Streptococcus pneumoniae (SPN), Lead author: Fritsche TR, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Antimicrobial Activity of BAL9141 Tested against Staphylococcal Strains with Selected Resistance Patterns, Lead author: Deshpande LM, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Activity of Tigecycline (TIG) Tested against Tetracycline-Resistant Enterobacteriaceae, Lead author: Fritsche TR, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Macrolide-Induction, Inoculum Effect and Kill-Curve Analysis of Telithromycin Tested against S. pneumoniae Strains with Characterized MLS_B Resistances, Lead author: Biedenbach DJ, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor (PDI), Lead author: Fritsche TR, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Antimicrobial Activity of LBM 415 (NVP PDF-713) Tested against Neisseria meningitidis (NM) and N. gonorrhoeae (NG), Lead author: Rhomberg PR, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Antimicrobial Activity and Spectrum of PPI-0903 (TAK-599), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains, Lead author: Sader HS, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Evaluation of PPI-0903 (TAK-599), a Novel Cephalosporin: Bactericidal Activity, Effects of Modifying Testing Parameters and Optimization of Disk Diffusion Tests, Lead author: Sader HS, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Evaluating Antimicrobial (ABX) Use & Bacterial Resistance (R): Comparison of the Statistical Power Achieved for Different Regression Methods, Lead author: Bhavnani SM, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Evaluation of Patients with ESBL- and Non-ESBL Producing Enterobacteriaceae (ETB): Outcomes Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Bhavnani SM, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

An Outbreak of Catalase-Negative Methicillin-Resistant Staphylococcus aureus, Lead author: Gales AC, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Validation of Etest for Antifungal Susceptibility Testing of 3 Agents using the FDA 510(k) Criteria for Antimicrobial Susceptibility Test (AST) Devices, Lead author: Bolmstrom A, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Antifungal Susceptibility Results from a Worldwide Anidulafungin Surveillance Program (2002-2003), Lead author: Messer S, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003), Lead author: Messer S, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Doripenem (DOR) International Surveillance: Antimicrobial Activity Against 16,008 Contemporary Pathogens (2003), Lead author: Fritsche TR, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Evaluation of the Reproducibility of MIC Results of Selected Newer Fluoroquinolones in Commercial Dry-Form Panels for Clinical Use, Lead author: Jones RN, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Monitoring For Antimicrobial Resistance in North American Haematology-Oncology Centers: Results from the CANCER Resistance Surveillance Program (USA; 2000-2002), Lead author: Fritsche TR, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Antimicrobial Activity of Daptomycin Tested Against Clinical Strains of Indicated Species Isolated in North American Medical Centers (2003), Lead author: Sader HS, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Inter-Method Comparison of Broth Microdilution and Agar Dilution Testing for Campylobacter spp.: Standardization of Broth Methods, Lead author: Fritsche TR, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Activity of Tigecycline (TIG) Tested Against Non-Fermentative Gram-negative (NFB) Bacilli other than P. aeruginosa, Lead author: Fritsche TR, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Antimicrobial Susceptibility of P. aeruginosa and Acinetobacter spp. from Bloodstream Infections (BSI): Comparison of SENTRY Program Results from North America, Latin America and Europe, Lead author: Sader HS, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Multi-Drug Resistant Pseudomonas aeruginosa, Co-Resistances in MYSTIC and SENTRY Programs, Lead author: Jones RN, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Influence of Patient Age on the Occurrence and Antimicrobial Resistance Trends of Isolates from Haemotology/Oncology Patients: Second Report from the CANCER Program (2001-2002), Lead author: Sader HS, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Susceptibility Testing Characteristics and Quality Control (QC) Guidelines for Omiganan Pentahydrochloride, A Topical Cationic Peptide, Lead author: Rennie R, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Antimicrobial Potency and Spectrum of Meropenem Versus Eleven Broad-Spectrum Agents: Report from the United States (US) MYSTIC Program (2003), Lead author: Rhomberg PR, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Dalbavancin MIC Testing: Validation and Test Reproducibility of Commercial Reagents, Lead author: Fritsche TR, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Occurrence, Persistence and Influence of Resistant Gram-Negative Clones: Report from the MYSTIC Programme (2003), Lead author: Jones RN, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Pharmacodynamics of levofloxacin (usual and high dose) and moxifloxacin versus Streptococcus pneumoniae from the SENTRY antimicrobial surveillance program (2002-2003) in elderly patients using Monte Carlo Analysis and population pharmacokinetics, Lead author: Owens Jr. RC, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

The emergence of VIM-2 in Latin American hospitals: report from the SENTRY Antimicrobial Surveillance Program, Lead author: Mendes RE, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Endemic and epidemic occurrences of metallo-beta-lactamases in Japanese medical centres (1998-2002): report from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial activity of the novel cephalosporin LB11058 tested against pathogens commonly associated with bacterial meningitis, Lead author: Sader HS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Substrate inhibition of the Pseudomonas aeruginosa metallo-beta-lactamase, SPM-1, in acidic and alkaline conditions, Lead author: Murphy TA, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Biochemical characterisation of IMP-16, a novel IMP variant harboured in a class I integron of a Pseudomonas aeruginosa clinical isolate from Brazil, Lead author: Mendes RE, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Frequency and antimicrobial susceptibility of bacterial pathogens isolated from bloodstream infections in haematology-oncology patients: results from the Latin America SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Andrade SS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Frequency of occurrence and antimicrobial susceptibility profile of pathogens causing bloodstream infections in paediatric patients from Latin America: report of SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Gales AC, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial spectrum and activity of NVP PDF-713 (PDF7), a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Potential utility of a peptide deformylase inhibitor, NVP PDF-713 (PDF7) against oxazolidinone-resistant or streptogramin-resistant Gram-positive isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Determination of quality control guidelines for MIC dilution and disk diffusion methods when testing NVP-PDF713, a novel peptide deformylase inhibitor, Lead author: Fritsche TR, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Determination of dry-form commercial reagent reproducibility and MIC validations for NVP-PDF713, a novel peptide deformylase inhibitor, Lead author: Moet G, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Once-weekly dalbavancin in catheter-related bloodstream infections: microbiological findings, Lead author: Goldstein BP, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Evaluations of Dalbavancin (DAL) activity and spectrum tested against European isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

In vitro activity of the glycylcycline tigecycline tested against a worldwide collection of 10,127 contemporary Staphylococci, Streptococci and Enterococci, Lead author: Fritsche TR, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial activity of tigecycline (GAR-936) tested against enterobacteriaceae, and selected non-fermentative Gram-negative bacilli, a worldwide sample, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic